+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Treatment of poor-prognosis, newly diagnosed acute myeloid leukemia with ara-C and recombinant human granulocyte-macrophage colony-stimulating factor



Treatment of poor-prognosis, newly diagnosed acute myeloid leukemia with ara-C and recombinant human granulocyte-macrophage colony-stimulating factor



Blood 75(9): 1766-1769



We administered recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) (120 micrograms/m2/d by continuous intravenous [IV] infusion) to 12 patients with newly diagnosed acute myeloid leukemia (AML) at relatively high risk of early death during remission induction. GM-CSF began 3 days after completion of induction chemotherapy (ara-C 1.5 g/m2 d x 4 days by continuous IV infusion after a 3 g/m2 bolus). Rates of fatal infection (42%), pneumonia and/or sepsis (83%), and CR (50%) did not differ significantly (P less than .05) from those observed after administration of the identical chemotherapy without GM-CSF to 53 historical controls with newly diagnosed AML at similarly high risk of early death. There were no significant differences between the GM-CSF-treated and the historical groups in the time required to reach neutrophil counts of 500 or 1,000/microL after administration of chemotherapy. Four patients died of infection before they could have benefited from the earliest recovery of neutrophil count observed in patients who entered CR. Growth of leukemia after GM-CSF administration was observed in only 1 of the 8 patients who survived long enough for response to induction therapy to be fully evaluated. This observation suggests that it might be safe to undertake larger, randomized studies, perhaps using earlier administration of GM-CSF, to definitively determine the role of GM-CSF added to chemotherapy in patients with newly diagnosed AML.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 041858624

Download citation: RISBibTeXText

PMID: 2184901


Related references

Effects of recombinant human granulocyte-macrophage colony stimulating factor in newly diagnosed high risk patients with acute myeloid leukemia. Proceedings of the American Association for Cancer Research Annual Meeting 36: 221, 1995

Effects of recombinant human granulocyte-macrophage colony stimulating factor on apoptosis and cell cycle kinetics in newly diagnosed high risk patients with acute myeloid leukemia. Blood 84(10 Suppl. 1): 586A, 1994

Recombinant granulocyte-colony stimulating factor as treatment for poor prognosis oligoblastic acute myeloid leukemia in elderly patients. Haematologica 92(1): 106-109, 2007

Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Blood 93(8): 2478-2484, 1999

Effect of priming with granulocyte-macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group. Leukemia 21(3): 453-461, 2007

Treatment of de novo acute myelogenous leukemia with recombinant granulocyte macrophage colony stimulating factor in combination with standard induction chemotherapy effect of granulocyte macrophage colony stimulating factor on white blood cell counts. Medical & Pediatric Oncology (Suppl. 2): 18-22, 1992

Experimental basis for the use of recombinant human granulocyte-macrophage colony-stimulating factor in patients with acute myeloid leukemia. Seminars in Oncology 21(6 Suppl 16): 39-43, 1994

Recombinant human granulocyte-macrophage colony-stimulating factor in combination with chemotherapy in acute myeloid leukemia after myelodysplastic syndromes. British Journal of Haematology 87(Suppl. 1): 120, 1994

Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapse. Blood 78(5): 1190-1197, 1991

Granulocyte-macrophage colony stimulating factor (GM-CSF) enhances the clinical responses to interferon-α (IFN) in newly diagnosed chronic myeloid leukemia (CML). Leukemia Research 38(8): 886-890, 2014

Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid leukemia. Blood 77(4): 700-711, 1991

Granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor and macrophage colony-stimulating factor in the treatment of acute myeloid leukemia and acute lymphoblastic leukemia. Leukemia Research 22(12): 1143-1154, 1998

Patterns of acute myeloid leukemia colony growth in response to recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF). Experimental Hematology 15(6): 652-656, 1987

In vivo biotherapy of acute myeloid leukemia with a recombinant fusion toxin targeted to the human granulocyte-macrophage colony-stimulating factor receptor. Proceedings of the American Association for Cancer Research Annual Meeting 38: 434, 1997

Treatment with recombinant human granulocyte colony-stimulating factor after chemotherapy for acute myeloid leukemia. Current Therapeutic Research 57(4): 268-277, 1996